Scinopharm Taiwan (TPE:1789) ROCE % : 4.16% (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Scinopharm Taiwan's annualized ROCE % for the quarter that ended in Dec. 2024 was 4.16%.

Scinopharm Taiwan ROCE % Historical Data

The historical data trend for Scinopharm Taiwan's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan ROCE % Chart

Scinopharm Taiwan Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

3.38

2.77

4.01

3.24

3.80

Scinopharm Taiwan Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															7.06	6.39	3.32	1.30	4.16

Scinopharm Taiwan ROCE % Calculation

Scinopharm Taiwan's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	421.1	/	( ( (11721.586 - 729.453)	+	(11942.738 - 767.682) )	/ 2 )
	=	421.1	/	( (10992.133	+	11175.056)	/ 2 )
	=	421.1	/	11083.5945
	=	3.80 %

Scinopharm Taiwan's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	463.496	/	( ( (11784.304 - 694.035)	+	(11942.738 - 767.682) )	/ 2 )
	=	463.496	/	( ( 11090.269	+	11175.056 )	/ 2 )
	=	463.496	/	11132.6625
	=	4.16 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Scinopharm Taiwan (TPE:1789) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Scinopharm Taiwan ROCE % Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Scinopharm Taiwan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144

Website

https://www.scinopharm.com

Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.

Scinopharm Taiwan Headlines

No Headlines